Here is how BioNTech SE Sponsored ADR (BNTX) and EUROFINS SCIENT (ERFSF) have performed compared to their sector so far this year.

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech (BNTX) recently witnessed a 13.9% increase in its share price over the last quarter. This period saw significant executive changes, including the upcoming departure of Chief Strategy Officer ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency's (EMA) Committee for ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...

The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call ...

Robeco Institutional Asset Management B.V. cut its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 23.5% in the first quarter, according to the company in its most ...

The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by risi ...